Episode
Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
- Podcast
- Hematologic Oncology Update
- Published
- Aug 13, 2026
- Duration seconds
- 7170
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hematologic-oncology-update-916423/episodes/non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-roles-of-car-t-cell-therapy-and-bispecific-antibodies/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hematologic-oncology-update-916423/non-hodgkin-lymphoma-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-roles-of-car-t-cell-therapy-and-bispecific-antibodies.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16) Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Abramson (51:10) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:13:24) Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies — Dr Brody (1:37:47) CME information and select publications